Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.5%

2 terminated/withdrawn out of 80 trials

Success Rate

97.3%

+10.8% vs industry average

Late-Stage Pipeline

48%

38 trials in Phase 3/4

Results Transparency

35%

25 of 72 completed trials have results

Key Signals

1 recruiting25 with results

Enrollment Performance

Analytics

Phase 3

31(43.1%)

Phase 2

23(31.9%)

Phase 4

7(9.7%)

Phase 1

7(9.7%)

N/A

4(5.6%)

72Total

Phase 3(31)

Phase 2(23)

Phase 4(7)

Phase 1(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (80)

Showing 20 of 80 trials

NCT04502966Phase 2Completed

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Role: collaborator

NCT05440643Phase 1Active Not Recruiting

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Role: lead

NCT07400718Not ApplicableCompleted

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

Role: collaborator

NCT07060885Phase 3Recruiting

A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

Role: lead

NCT05655858Completed

Observational Study of Allergic Rhinitis in Children

Role: lead

NCT07013123Phase 3Not Yet Recruiting

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

Role: collaborator

NCT04878354Phase 3Completed

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis

Role: lead

NCT04881461Phase 3Completed

A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis

Role: lead

NCT04145219Phase 3Completed

House Dust Mite Allergy Trial In Children

Role: lead

NCT01433510Phase 4Completed

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

Role: lead

NCT00135629Phase 3Completed

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

Role: collaborator

NCT06151938Enrolling By Invitation

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Role: lead

NCT03654976Phase 3Completed

Mite Asthma Pediatric Immunotherapy Trial

Role: lead

NCT00135642Phase 3Completed

Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma

Role: collaborator

NCT05476484Unknown

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma

Role: lead

NCT04541004Phase 3Completed

Adolescent Mite Allergy Safety Evaluation

Role: lead

NCT05881577Unknown

The Effect of Allergic Rhinitis on Educational Outcomes

Role: lead

NCT04176185Phase 3Terminated

A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber

Role: lead

NCT05119751Phase 4Completed

Vestibular Versus Sublingual Route of AIT Tablets

Role: collaborator

NCT04100902Phase 4Completed

The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma

Role: collaborator